NCT06980961 Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis
| NCT ID | NCT06980961 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Science Valley Research Institute |
| Condition | Stasis Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-05-20 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-05-20 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study tests two types of lasers (ND YAG 1064 short and ultra-short pulses) to treat hyperchromic skin lesions secondary to venous hypertension (stasis dermatitis)
Eligibility Criteria
Inclusion Criteria: 1. Women or men aged 18 to 89 years with stasis dermatitis secondary to venous hypertension 2. Agreement with the terms of the survey and signing of the informed consent form 3. Availability to make the necessary appointments for treatment and follow-up 4. Provide consent to avoid pregnancy during treatment 5. Have primary venous hypertension already treated (treatment of varicose veins of the lower limbs) by any of the available techniques Exclusion Criteria: 1. Men and women with CEAP 2 to 6, low mobility, no stasis dermatitis. 2. Peripheral arterial disease. 3. History of known allergy to the drugs used in this study 4. Presence of other types of dermatitis in the lower extremities, such as allergic stasis eczema. 5. Presence of comorbidities (such as diabetes mellitus, heart failure, respiratory failure, hypertension, hypothyroidism, or hyperthyroidism), pregnancy, breastfeeding, pulmonary hypertension, deep vein thrombosis (DVT), family history of DVT, known hypercoagulable states or thrombophilia, asthma, and migraine. 6. Anyone who does not agree with any of the search terms. \-
Contact & Investigator
Eduardo Ramacciotti, MD, Ph.D, livre docente
STUDY CHAIR
Science Valley Research Institute
Frequently Asked Questions
Who can join the NCT06980961 clinical trial?
This trial is open to participants of all sexes, studying Stasis Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06980961 currently recruiting?
Yes, NCT06980961 is actively recruiting participants. Contact the research team at val.aguiarvasc@gmail.com for enrollment information.
Where is the NCT06980961 trial being conducted?
This trial is being conducted at Santo André, Brazil.
Who is sponsoring the NCT06980961 clinical trial?
NCT06980961 is sponsored by Science Valley Research Institute. The principal investigator is Eduardo Ramacciotti, MD, Ph.D, livre docente at Science Valley Research Institute. The trial plans to enroll 20 participants.